PMID- 38306152
OWN - NLM
STAT- MEDLINE
DCOM- 20240205
LR  - 20240206
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 23
IP  - 2
DP  - 2024 Feb 1
TI  - INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and 
      Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study.
PG  - SF405634s12-SF405634s18
LID - 10.36849/JDD.SF405634 [doi]
AB  - BACKGROUND: Patient-reported outcomes (PROs) are emerging as a fundamental 
      component of disease impact assessment in acne vulgaris (AV), complementing 
      clinician-reported outcomes. No data is available on PROs for patients with AV 
      using sarecycline in real-world settings. METHODS: A single-arm, prospective 
      cohort study that included patients ≥9 years old diagnosed with moderate or 
      severe non-nodular AV was implemented as part of routine care in clinical 
      practices (N=30). Patients received oral sarecycline (60 mg, 100 mg, or 150 mg) 
      for 12 weeks, as part of usual care. The primary endpoint was Acne Symptom and 
      Impact Scale (ASIS) responses from patients (≥12 years) and caregivers (for 
      patients 9-11 years) at week 12 and change from baseline (CFB). 
      Investigator’s Global Assessment (IGA) of AV severity and adverse events 
      (AEs) were also recorded. RESULTS: A total of 253 patients with AV completed the 
      study (adults: 60.1%, females: 77.6%). ASIS mean scores significantly decreased 
      (P <.0001) at week 12 for: signs (mean CFB ± standard deviation [SD]: 
      –0.8 ± 0.7), impact (–1.0 ± 1.0), emotional impact 
      (–1.2 ± 1.1), and social impact (0.6 ± 1.1). Significant 
      reductions in AV severity (P <.0001) were reported by patients and caregivers. 
      The IGA success rate was 58.9% and physician satisfaction with treatment outcomes 
      was 88.1%. A total of 31 (10.3%) patients reported ≥1 AE during the study. 
      CONCLUSIONS: Patients with moderate-to-severe AV receiving acne management with 
      an oral antibiotic for 12 weeks experienced a significant improvement in 
      AV-related symptoms and psychosocial burden. J Drugs Dermatol. 2024;23:1(Suppl 
      1):s12-18.
FAU - Baldwin, Hilary E
AU  - Baldwin HE
FAU - Graber, Emmy
AU  - Graber E
FAU - Harper, Julie C
AU  - Harper JC
FAU - Alexis, Andrew F
AU  - Alexis AF
FAU - Stein Gold, Linda
AU  - Stein Gold L
FAU - Kircik, Leon
AU  - Kircik L
FAU - Del Rosso, James
AU  - Del Rosso J
FAU - Hebert, Adelaide A
AU  - Hebert AA
FAU - Rieder, Evan A
AU  - Rieder EA
FAU - Fried, Richard G
AU  - Fried RG
FAU - Narayanan, Siva
AU  - Narayanan S
FAU - Koscielny, Volker
AU  - Koscielny V
FAU - Kasujee, Ismail
AU  - Kasujee I
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 94O110CX2E (sarecycline)
RN  - 0 (Immunoglobulin A)
RN  - 0 (Tetracyclines)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Child
MH  - Male
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - *Acne Vulgaris/diagnosis/drug therapy
MH  - Treatment Outcome
MH  - Immunoglobulin A/therapeutic use
MH  - *Tetracyclines
EDAT- 2024/02/02 12:44
MHDA- 2024/02/05 06:43
CRDT- 2024/02/02 11:45
PHST- 2024/02/05 06:43 [medline]
PHST- 2024/02/02 12:44 [pubmed]
PHST- 2024/02/02 11:45 [entrez]
AID - S1545961624SSF405634s12X [pii]
AID - 10.36849/JDD.SF405634 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2024 Feb 1;23(2):SF405634s12-SF405634s18. doi: 
      10.36849/JDD.SF405634.